For the quarter ending 2026-03-31, LFCR made $23,193K in revenue. -$15,934K in net income. Net profit margin of -68.70%.
| Income Statement | 2026-03-31 | 2025-02-23 | 2024-11-24 | |
|---|---|---|---|---|
| Revenues | 23,193 | 35,154 | 32,564 | |
| Cost of sales | 18,731 | 25,309 | 21,480 | |
| Gross profit | 4,462 | 9,845 | 11,084 | |
| Restructuring costs (recovery) | - | -115 | - | |
| Research and development expenses | 1,217 | 2,045 | 1,924 | |
| Selling, general, and administrative expenses | 7,917 | 10,093 | 11,119 | |
| Total operating costs and expenses | - | - | 13,043 | |
| Loss on sale or disposal of assets, net of portion classified as cost of sales | 0 | -6,851 | - | |
| Operating loss | -4,672 | -9,029 | -1,959 | |
| Interest income | 128 | - | - | |
| Interest expense-Nonrelated Party | 454 | - | - | |
| Interest expense, net | - | -5,481 | - | |
| Interest expense-Related Party | 6,894 | - | - | |
| Change in fair value of debt derivative liability, related party | -3,155 | -600 | 1,200 | |
| Interest expense, net | - | - | 5,465 | |
| Other income, net | 110 | 333 | -304 | |
| Loss before income taxes | -14,937 | -14,777 | -6,528 | |
| Income tax (expense) benefit | 43 | -8 | 43 | |
| (loss) income from continuing operations | - | -14,769 | -6,571 | |
| Net loss | -14,980 | -14,769 | -6,571 | |
| Preferred stock dividends | 907 | 2,466 | - | |
| Fair value of conversion ratio improvement to preferred stockholders | - | - | 2,132 | |
| Accretion of preferred stock to redemption value | 47 | 144 | - | |
| Loss available to common stockholders | -15,934 | -17,379 | -8,703 | |
| Basic EPS | -0.43 | -0.47 | -0.25 | |
| Diluted EPS | -0.43 | -0.47 | -0.25 | |
| Basic Average Shares | 37,477,386 | 37,020,570 | 34,360,657 | |
| Diluted Average Shares | 37,477,386 | 37,020,570 | 34,360,657 | |
LIFECORE BIOMEDICAL, INC. DE (LFCR)
LIFECORE BIOMEDICAL, INC. DE (LFCR)